|
The
company also raised its full-year profit and revenue forecast
for the second time in as many months.
Pfizer's shares were up about 4 percent in premarket trading.
Net income fell to $2.13 billion, or 34 cents per share, in the
third quarter, from $2.67 billion, or 42 cents per share, a year
earlier.
On an adjusted basis, the company earned 60 cents per share,
above the analysts' average estimate of 51 cents per share,
according to the Thomson Reuters I/B/E/S.
Revenue fell 2 percent to $12.09 billion, but was above the
analysts' estimate of $11.56 billion.
The largest U.S. drugmaker said revenue from its global vaccines
business rose 43 percent to $1.63 billion. The unit, which
includes the Prevnar 13 pneumonia vaccine, contributed about
13.5 percent to the company's total revenue.
Pfizer raised its 2015 revenue range by $1 billion to $47.5
billion-$48.5 billion.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
